摘要:
Antiallergic imidazo[1,2-a](pyrrolo, thieno or furano)[2,3-d]azepines of formula (I), the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R1 represents hydrogen, C¿1-4?alkyl, halo, ethenyle substituted with hydroxycarbonyl or C1-4alkyloxycarbonyl, hydroxyC1-4alkyl, formyl, hydroxycarbonyl or hydroxycarbonylC1-4alkyl; R?2¿ represents hydrogen, C¿1-4?alkyl, ethenyl substituted with hydroxycarbonyl or C1-4alkyloxycarbonyl, C1-4alkyl substituted with hydroxycarbonyl or C1-4alkyloxycarbonyl, hydroxyC1-4alkyl, formyl or hydroxycarbonyl; R?3¿ represents hydrogen, C¿1-4?alkyl, hydroxyC1-4alkyl, phenyl or halo; X represents O, S or NR?4¿; L represents hydrogen; C¿1-6?alkyl; substituted C1-6alkyl; C3-6alkenyl; C3-6alkenyl substituted with aryl; or a radical of the formula: -Alk-Y-Het?1¿ (a-1), -Alk-NH-CO-Het2 (a-2) or Alk-Het3 (a-3). Compositions comprising said compounds, processes of preparing the same and intermediates in the preparation thereof.
摘要:
wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
摘要:
wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
摘要:
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R?1 and R2¿ each independently are hydrogen; C¿1-6?alkyl; difluoromethyl; trifluoromethyl; C3-6cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C1-6alkylsulfonyl; arylsulfonyl; or substituted C1-10alkyl; R?3¿ is hydrogen, halo or C¿1-6?alkyloxy; =C=X is a bivalent radical of formula =C=O; =C=CH-R?4¿; =C=N-O-R5; or formula (a-4); Alk is C¿1-4?alkanediyl; -A-B- is a bivalent radical of formula: -CR?6=CR7¿- or -CHR6-CHR7-; L is hydrogen; optionally substituted C¿1-6?alkyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C3-6alkenyl; optionally substituted piperidinyl; C1-6alkylsulfonyl or arylsulfonyl; aryl is optionally substituted phenyl; Het?1¿ is morpholinyl or optionally substituted pyridinyl, -furanyl, -thienyl, -hydroxypyridinyl, -imidazolyl, -thiazolyl, -oxazolyl, -isoquinolinyl, -quinolinonyl, -piperidinyl, -piperazinyl; and Het2 is morpholinyl or optionally substituted piperidinyl, -piperazinyl, -pyridinyl, -furanyl or -thienyl; having PDE IV and cytokine inhibiting activity. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions thereof.
摘要:
The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceuticlaly acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R?1 and R2¿ each independently are hydrogen; C¿1-6?alkyl; difluoromethyl; trifluoromethyl; C3-6cycloalkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C1-6alkylsulfonyl; arylsulfonyl; or substituted C1-10alkyl; R?3¿ is hydrogen, halo or C¿1-6?alkyloxy; R?4¿ is hydrogen; cyano; optionally substituted C¿1-6?alkyl; C1-6alkyloxycarbonyl or aryl; R?5¿ is hydrogen; cyano; optionally substituted C¿1-6?alkyl; C1-6alkyloxycarbonyl or aryl; Y is a direct bond or C1-3alkanediyl; -A-B- is a bivalent radical of formula -CR?6=CR7¿- or -CHR6-CHR7-; L is hydrogen; optionally substituted C¿1-6?alkyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; C1-6alkylsulfonyl or arylsulfonyl; aryl is optionally substituted phenyl; Het is morpholinyl or optionally substituted piperidinyl, -piperazinyl, -pyridinyl; -furanyl or -thienyl; having PDE IV and cytokine inhibiting acitivity. Further, pharmaceutical compositions, preparations and use as a medicine are described.
摘要:
La présente invention concerne de nouvelles imidazo[1,2a](pyrrolo, thiéno ou furano)[3,2-d]azépines de la formule (I); les sels d'adition pharmaceutiquement acceptables et les formes stéréochimiquement isomères de celles-ci, dans laquelle chacune des lignes pointillées représentent indépendamment une liaison optionnelle; R1 représente hydrogène, C1-4 alkyle, halo, éthényle substitué avec hydroxycarbonyle ou C1-4alkyloxycarbonyle, hydroxyC1-4alkyle, formyle, hydroxycarbonyle ou hydroxycarbonylC1-4alkyle; R2 représente hydrogène, C1-4 alkyle, éthényle substitué avec hydroxycarbonyle ou C1-4alkyloxycarbonyl hydroxyC1-4alkyle, formyle ou hydroxycarbonyle; R3 représente hydrogène, C1-4 alkyle, hydroxyC1-4 alkyle, phényle ou halo; L représente hydrogène; C1-6alkyle; C1-6alkyle substitué avec un substituant choisi dans le groupe comprenant hydroxy, halo, C1-4alkyloxy, hydroxycarbonyle, C1-4alkyloxycarbonyle, C1-4alkyloxycarbonylC1-4alkyloxy, hydroxycarbonylC1-4alkyloxy, C1-4alkyloxycarbonylamino, C1-4alkylaminothiocarbonylamino, aryle aryloxy et arylcarbonyle; C1-6 alkyle substitué avec hydroxy et aryloxy; C3-6alcényle; C3-6alcényle substitué avec aryle; L représente un radical de la formule-Alk-Y-Het1 (a-1), -Alk-NH-CO-Het2 (a-2) ou -Alk-Het3 (a-3); ils sont utilisés comme composés antiallergiques. Compositions comprenant lesdits composés, méthodes d'utilisation et procédés pour leur préparation.
摘要:
La présente invention concerne de nouvelles imidazo[2,1-b][3]benzazépines de la formule (I), les sels d'addition pharmaceutiquement acceptables et les formes stéréochimiquement isomerés de celles-ci, dans laquelle chacune des lignes pointillées représente indépendamment une liaison optionnelle; R1 représente hydrogène, halo, C1-4alkyle ou C1-4alkyloxy; R3 représente hydrogène, C1-4alkyle, éthényle substitué avec hydroxycarbonyle ou C1-4alkyloxycarbonyle, C1-4alkyle substitué avec hydroxycarbonyle ou C1-4 alkyloxycarbonyle, hydroxy-C1-4alkyle, formyle ou hydroxycarbonyle; R4 représente hydrogène, C1-4alkyle, hydroxyC1-4alkyle, phényle ou halo; R5 représente hydrogène, C1-4alkyle ou halo; L représente hydrogène; C1-6alkyle; C1-6alkyle substitué avec un substituant choisi dans le groupe comportant hydroxy, halo, C1-4alkyloxy, hydroxycarbonyle, C1-4alkyloxycarbonyle, C1-4alkyloxycarbonyle-C1-4alkyloxy, hydroxycarbonyleC1-4alkyloxycarbonylamino, C1-4alkylaminocarbonyle, C1-4alkylaminocarbonylamino, C1-4alkylaminothiocarbonylamino, aryle, aryloxy et arylcarbonyle; C1-6alkyle substitué avec hydroxy et aryloxy; C3-6alcényle; C3-6alcényle substitué avec aryle; ou bien, L représente un radical de la formule -Alk-Y-Het1 (a-1), -Alk-NH-CO-Het2 (a-2) ou -Alk-Het3 (a-3); à condition que 6,11-dihydro-11-(4-pipéridinylidène)-5-H-imidazo[2,1-b][3]benzazépine soit exclu; ils sont utilisés comme composés antiallergiques. Compositions contenant lesdits composés, méthodes d'utilisation et procédés pour leur préparation.